J Cancer
2020; 11(11):3357-3368.
doi:10.7150/jca.40729 This issueCite
Research Paper
Analysis of lncRNA, miRNA and mRNA-associated ceRNA networks and identification of potential drug targets for drug-resistant non-small cell lung cancer
1. Department of Pharmacy, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. 2. Henan Key Laboratory of Precision Clinical Pharmacy, Zhengzhou University, Zhengzhou, China. 3. Department of Otolaryngology Head and Neck Surgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. *These authors contributed equally to this work.
✉ Corresponding author: Xiangzhen Kong, Department of Pharmacy, the First Affiliated Hospital of Zhengzhou University, Henan Key Laboratory of Precision Clinical Pharmacy, No.1 Jianshe road, Zhengzhou, Henan, China 450052. Tel. +86-371-6629-5652, Email: fcckongxzedu.cn.More
Citation:
Kong X, Hu S, Yuan Y, Du Y, Zhu Z, Song Z, Lu S, Zhao C, Yan D. Analysis of lncRNA, miRNA and mRNA-associated ceRNA networks and identification of potential drug targets for drug-resistant non-small cell lung cancer. J Cancer 2020; 11(11):3357-3368. doi:10.7150/jca.40729. https://www.jcancer.org/v11p3357.htm
Background: Drug resistance to chemotherapeutic drugs or targeted medicines is an obstacle encountered in the treatment of non-small-cell lung cancer (NSCLC). However, the mechanisms of competing endogenous RNA (ceRNA) on the drug resistance in NSCLC are rarely reported. In this paper, the comprehensive expression profiles of lncRNAs and mRNAs in drug-resistant NSCLC cells were obtained by RNA sequencing.
Methods: The dysregulated lncRNAs, miRNAs and mRNAs in drug-resistant NSCLC cell lines were identified by RNA-sequencing and bioinformatics methods.
Results: A total of 39 dysregulated lncRNAs and 650 dysregulated mRNAs were identified between drug-resistant NSCLC cell lines and their parental cell lines. Additionally, 33 lncRNA-miRNA-mRNA pathways in the ceRNA network in drug-resistant NSCLC were constructed through bioinformatics methods and ceRNA regulatory rules. These comprised 12 dysregulated lncRNAs, five dysregulated miRNAs, and eight dysregulated mRNAs. In addition, lncRNA ATP2B1/miR-222-5p/TAB2 and lncRNA HUWE1/miR-222-5p/TAB2 were identified as potential ceRNA networks involved in drug resistance to NSCLC.
Conclusions: The current study provides a promising therapeutic strategy against the lncRNA-miRNA-mRNA ceRNA regulatory network for NSCLC treatment and deepens our comprehension of the ceRNA regulatory mechanisms related to drug resistance to NSCLC.
Kong, X., Hu, S., Yuan, Y., Du, Y., Zhu, Z., Song, Z., Lu, S., Zhao, C., Yan, D. (2020). Analysis of lncRNA, miRNA and mRNA-associated ceRNA networks and identification of potential drug targets for drug-resistant non-small cell lung cancer. Journal of Cancer, 11(11), 3357-3368. https://doi.org/10.7150/jca.40729.
ACS
Kong, X.; Hu, S.; Yuan, Y.; Du, Y.; Zhu, Z.; Song, Z.; Lu, S.; Zhao, C.; Yan, D. Analysis of lncRNA, miRNA and mRNA-associated ceRNA networks and identification of potential drug targets for drug-resistant non-small cell lung cancer. J. Cancer 2020, 11 (11), 3357-3368. DOI: 10.7150/jca.40729.
NLM
Kong X, Hu S, Yuan Y, Du Y, Zhu Z, Song Z, Lu S, Zhao C, Yan D. Analysis of lncRNA, miRNA and mRNA-associated ceRNA networks and identification of potential drug targets for drug-resistant non-small cell lung cancer. J Cancer 2020; 11(11):3357-3368. doi:10.7150/jca.40729. https://www.jcancer.org/v11p3357.htm
CSE
Kong X, Hu S, Yuan Y, Du Y, Zhu Z, Song Z, Lu S, Zhao C, Yan D. 2020. Analysis of lncRNA, miRNA and mRNA-associated ceRNA networks and identification of potential drug targets for drug-resistant non-small cell lung cancer. J Cancer. 11(11):3357-3368.
This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.